Page last updated: 2024-09-05

erlotinib hydrochloride and Ewing Sarcoma

erlotinib hydrochloride has been researched along with Ewing Sarcoma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bandyopadhyay, A; Favours, E; Ghilu, S; Guttridge, D; Hirotani, K; Houghton, PJ; Kurmashev, D; Kurmasheva, RT; London, C; Michalek, J; Phelps, DA; Pozo, VD; Trevino, A; Zhang, L	1

Other Studies

1 other study(ies) available for erlotinib hydrochloride and Ewing Sarcoma

Article	Year
Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models. Pediatric blood & cancer, 2018, Volume: 65, Issue:2 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Broadly Neutralizing Antibodies; Cell Line, Tumor; Erlotinib Hydrochloride; Female; Humans; Mice; Mice, SCID; Receptor, ErbB-3; Sarcoma, Ewing; Xenograft Model Antitumor Assays	2018

Article

Year

Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models.

Pediatric blood & cancer, 2018, Volume: 65, Issue:2

Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Broadly Neutralizing Antibodies; Cell Line, Tumor; Erlotinib Hydrochloride; Female; Humans; Mice; Mice, SCID; Receptor, ErbB-3; Sarcoma, Ewing; Xenograft Model Antitumor Assays

2018